Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX  
287.24
+5.45 (+1.93%)
Products, Regulatory

Vertex Presents New Data From Vx-880 Phase 1/2 Clinical Trial

Published: 06/06/2022 14:06 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Presents New Data From Vx-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions.
Vertex Pharmaceuticals Inc- Vx-880 Generally Well Tolerated in All Patients Dosed to Date.
Vertex Pharmaceuticals Inc- Majority of Adverse Events Were Mild Or Moderate for Vx-880.
Vertex Pharma -presentation Included Data From Both Patients Dosed in Part a of Study, Designed to Assess Safety Profile of Vx-880 at Half Target Dose.
Vertex Pharmaceuticals Inc- to Date, Three Patients Have Been Dosed in Phase 1/2 Study With Vx-880.
Vertex Pharmaceuticals Inc - Third Patient Has Received Full Target Dose in Part B of Study.